ArticleInternal medicine (Tokyo, Japan)2022

Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma.

Rie Sugimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.